Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C

Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):80-3.

Abstract

Background: Hepatitis C virus (HCV) is a worldwide common disease. Some predictive factors influencing the response to interferon alpha (IFN-alpha) therapy have been identified, but the conclusions differ in various counties and areas. The aim of this study was to study the associations between HCV genotypes, HLA-DRB alleles and their response to IFN-alpha and ribavirin in Chinese patients with chronic hepatitis C in Northeast China.

Methods: HCV genotypes of 113 patients with HCV were investigated. Gene chips were used to analyze the frequency of HLA-DRB in 25 of these patients and their response to IFN-alpha and ribavirin. The associations of HCV genotypes, HLA-DRB alleles and their response to IFN-alpha and ribavirin were also studied.

Results: The response rates differed in several types of HCV, with HCV 2b being the highest (57.78%), HCV 1a and 2a lower (46.15% and 47.62%) and HCV 1b the lowest (11.76%). The response rates to IFN-alpha and ribavirin in patients with DRB1*07 were higher than those with DRB1*04. Sex, HCV type and HLA-DRB were all related to the response. Most female patients with HCV 2b and HLA-DRB1*07 presented complete response, whereas male patients with HCV 1b and HLA-DRB1*04 usually demonstrated no response. DRB1*07 allele and HCV 2b were the factors closely related to the response.

Conclusions: The response rate of HCV 1b may be the lowest even IFN-alpha and ribavirin are combined in treatment. Not only virus but also the host plays an important role in anti-virus therapy. Thus, it is necessary to adjust the host's immune status to accelerate the clearance of HCV.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Genetic Markers
  • Genotype
  • HLA-DR Antigens / drug effects*
  • HLA-DR Antigens / genetics
  • HLA-DRB1 Chains
  • Hepacivirus / drug effects*
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics*
  • Hepatitis C, Chronic / mortality
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Liver Function Tests
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Genetic Markers
  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Ribavirin